cirrhotic PH, n = 12 | non-cirrhotic PH, n = 13 | all patients, n = 25 | |
---|---|---|---|
PSE indications: n (%) | |||
Persistent EVH | 4 (33.3%) | 3 (23.1%) | 7 (28.0%) |
Persistent GVH | 2 (16.7%) | 4 (30.8%) | 6 (24.0%) |
Recurrent EVH | 1 (8.3%) | 1 (7,7%) | 2 (8%) |
Recurrent GVH | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) |
Controlled EVH with high risk of recurrent bleeding | 4 (33.3%) | 4 (30.8%) | 8 (32.0%) |
Controlled GVH with high risk of rebleeding | 0 (0.0%) | 1 (7.7%) | 1 (4.0%) |
Recurrent portal hypertensive gastropathy bleeding | 1 (8.3%) | 0 (0.0%) | 1 (4.0%) |
NSBB failure: n (%) | 10 (83.3%) | 11 (84.6%) | 21 (84.0%) |
TIPS contraindications: n (%) | |||
TIPS anatomically not possible | 4 (33.3) | 9 (69.2) | 13 (52.0) |
Bilirubin > 5 mg/dl | 3 (25.0) | 0 (0.0) | 3 (12.0) |
TIPS not reasonable due to portal hemodynamics | 2 (16.7) | 4 (30.8) | 6 (24.0) |
TIPS failure with recurrent variceal bleeding | 2 (16.7) | 0 (0.0) | 2 (8.0) |
Right heart failure | 1 (8.4) | 0 (0.0) | 1 (4.0) |